Resultados de Búsqueda
Lenvatinib plus everolimus is recommended as an option for treating advanced renal cell carcinoma in adults who have had 1 previous vascular endothelial growth factor (VEGF)-targeted therapy.
NICE
National Institute for Health and Clinical Excellence (NICE)
Only if: - their Eastern Cooperative Oncology Group (ECOG) performance status score is 0 or 1 - the company provides lenvatinib with the discount agreed in the patient access scheme. This recommendation is not intended to affect treatment with lenvatinib plus everolimus that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, ...
ver más ... 2018Tivozanib is recommended as an option for treating advanced renal cell carcinoma in adults
NICE
National Institute for Health and Clinical Excellence (NICE)
Only if: - they have had no previous treatment and - the company provides tivozanib with the discount agreed in the patient access scheme. This recommendation is not intended to affect treatment with tivozanib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate ...
ver más ... 2018Cabozantinib is recommended, within its marketing authorisation, for adults with untreated advanced renal cell carcinoma that is intermediate‑ or poor‑risk as defined in the International ...
NICE
National Institute for Health and Clinical Excellence (NICE)
Current treatment for untreated advanced renal cell carcinoma is usually pazopanib or sunitinib. Clinical trial evidence shows that cabozantinib extends the time until cancer progresses compared with current treatment. But the evidence on whether cabozantinib increases how long people live is less certain. It appears to be at least as effective as current treatment, but it's not clear how much extra benefit it offers. Cost-effectiveness estimates for cabozantinib compared with current ...
ver más ... 2018Do recommend low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy. Current evidence shows no major safety concerns. Evidence on efficacy is ...
NICE
National Institute for Health and Clinical Excellence (NICE)
ver más ... 2018
Pirfenidone is recommended as an option for treating idiopathic pulmonary fibrosis in adults only if: the person has a forced vital capacity (FVC) between 50% and 80% predicted, the company provides ...
NICE
National Institute for Health and Clinical Excellence (NICE)
This recommendation is not intended to affect treatment with pirfenidone that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.
ver más ... 2018